Danaher Enters Stem Cell Medicine with Strategic Collaboration to Advance Clinical Translation

Shanghai Tongjin Stem Cell Technology Co., Ltd. is a high-tech enterprise established by Professor Liu Zhongmin's team from Dongfang Hospital, affiliated with Tongji University, bringing together the core research team of the stem cell base and regenerative medicine institute. This strategic cooperation is another significant achievement under the guidance of Danaher's "Dual Innovation Acceleration Engine" strategy.Promote Clinical and Academic Innovation Transformation, Open a New Chapter of Local Innovation Transformation in China.

"Golden Stem Cell-Danaher Innovation and Transformation Joint Research Institute"Will focus on new discoveries in life science research, new clinical diagnosis and treatment technologies, and clinical transformation applications, jointly promoting medical research, achievement transformation, and the development of the healthcare industry. In addition, Tongjin Stem Cells will also collaborate with Danaher to plan and...Build a research and development experimental platform.Based on the research and clinical research direction of gold stem cells,Danaher will provide cutting-edge scientific research solutions,Accelerate the development and transformation of scientific research and technological applications.

Stem cell technology, as a hot spot and frontier field in the current biopharmaceutical industry, is one of the most promising research areas for transformation. It is hailed as the third medical revolution following drug treatment and surgical treatment, demonstrating extraordinary therapeutic potential in the fields of major chronic diseases, difficult and complicated disorders, anti-aging, and tissue repair.

Danaher looks forward to collaborating with Tongjin Stem Cells to accelerate the resolution of technical challenges in the production and transition of stem cells.Promote the standardized and intelligent production of stem cell technologies and products,Promote the rapid approval of stem cell drugs through national inspections, injecting new momentum into the development of the stem cell industry.